Improvements in prostate brachytherapy dosimetry due to seed stranding

Brachytherapy

Volumn 6, Issue 1, 2007, Pages 44-48

  Lin, Kevin ^a   Lee, Steve P ^a   Cho, Jennifer S ^b   Reiter, Robert E ^b   DeMarco, John J ^a   Solberg, Timothy D ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Loose seeds; Prostate cancer; Seed stranding; Suture embedded seeds

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DOSIMETRY; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SUTURING METHOD;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES;

EID: 33846605952     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2006.08.010     Document Type: Article

References (34)

1. American Cancer Society, Inc., Cancer facts and figures, 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf.
2. Adolfsson J., Brehmer M., Naslund E., et al. Iodine-125 brachytherapy for clinically localized prostate cancer: A 5-year follow-up of outcome and complications. Eur Urol 26 (1994) 207-211
3. Sharkey J., Cantor A., Solc Z., et al. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep 3 (2002) 250-257
4. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
5. Wallner K., Roy J., and Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 14 (1996) 449-453
6. Ragde H., Grado G.L., and Nadir B.S. Brachytherapy for clinically localized prostate cancer: Thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 54 (2001) 739-747
7. Blasko J.C., Grimm P.D., and Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 3 (1993) 240-249
8. Al-Qaisieh B., Carey B., Ash D., et al. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 397-399
9. Nag S., Vivekanandam S., and Martinez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 39 (1997) 667-670
10. Davis B.J., Pfeifer E.A., Wilson T.M., et al. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol 164 (2000) 1661
11. Merrick G.S., Butler W.M., Wallner K.E., et al. Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol 175 (2006) 1376-1380
12. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 437-447
13. Potters L., Huang D., Calugaru E., et al. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology 62 (2003) 1073-1077
14. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
15. Nath R., Roberts K., Ng M., et al. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys 25 (1998) 2293-2307
16. Wallner K., Merrick G., True L., et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
17. Lee W.R., deGuzman A.F., Tomlinson S.K., et al. Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiother Oncol 65 (2002) 123-127
18. Fagundes H.M., Keys R.J., Wojcik M.F., et al. Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPID Strand: A dosimetric analysis. Brachytherapy 3 (2004) 136-140
19. Fuller D.B., Koziol J.A., and Feng A.C. Prostate brachytherapy seed migration and dosimetry: Analysis of stranded sources and other potential predictive factors. Brachytherapy 3 (2004) 10-19
20. Reed D.R., Wallner K.E., Mueller A., et al. Rapid Strand vs. loose (Iodine-125 seeds): A prospective randomized trial. Brachytherapy 4 (2005) 113
21. Kaplan I.D., Meskell P.M., Lieberfarb M., et al. A comparison of the precision of seeds deposited as loose seeds versus suture embedded seeds: A randomized trial. Brachytherapy 3 (2004) 7-9
22. Crook J. The pros and cons of linked versus loose seeds. Radiother Oncol 69 Suppl. 1 (2003) S39
23. McLaughlin P., Narayana V., Pan C., et al. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds. Int J Radiat Oncol Biol Phys 64 (2006) 144-150
24. Stock R.G., Nelson N.S., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
25. Papagikos M.A., Deguzman A.F., Rossi P.J., et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy 4 (2005) 252-258
26. Stock R.G., Stone N.N., Kao J., et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: Implications for treatment optimization. Cancer 89 (2000) 1829-1834
27. Stock R.G., Stone N.N., Dahlal M., et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 1 (2002) 83-89
28. Crook J. Commentary on "a comparison of the precision of seeds deposited as loose seeds vs. suture-embedded seeds: A randomized trial" and "prostate brachytherapy seed migration and dosimetry: Analysis of stranded sources and other potential predictive factors": To strand or not to strand-Is this really the question?. Brachytherapy 3 (2004) 20-21
29. McNeely L.K., Stone N.N., Presser J., et al. Influence of prostate volume on dosimetry results in real-time 125I seed implantation. Int J Radiat Oncol Biol Phys 58 (2004) 292-299
30. Yu Y., Waterman F.M., Suntharalingam N., et al. Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. Int J Radiat Oncol Biol Phys 34 (1996) 717-725
31. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
32. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
33. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
34. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996